Foord Global Equity Fund (Luxembourg)
For long-term investors in global equity securities
The fund aims to achieve optimum risk-adjusted returns by investing in a diversified portfolio of global equities and related securities. It seeks to outperform the MSCI All Country World Net Total Return Index after fees, without assuming greater risk.
- With a moderate to high risk profile
- Seeking long-term capital growth
- And able to withstand investment volatility in the short to medium term.
Belgium, France, Japan, Luxembourg, South Africa, Switzerland, United Kingdom.
|Year||Fund Return %||Benchmark Return %|
|2013 (from 02/Apr)||14.1||15.8|
MSCI All Country World Total Return Index.
Longer than five years.
2 April 2013
|Initial subscription amount||
US$10,000 or equivalent
|Subsequent subscription amount||
US$ 1,000 or equivalent
Complies with UCITS regulations. In addition, the Fund cannot enter into total return swaps, securities lending transactions, repurchase transactions or reverse repurchase transactions or any other securities financing transactions. Only listed derivatives can be used for efficient portfolio management.
A roll-up fund with income being reinvested in the portfolio.
Zero income yield as it does not distribute its income.
Investing in quality global equities that presents compelling long-term value. Global equity exposure typically between 90% and 100%, with balance invested in cash and money market instruments.
The fund is actively managed and not constrained by the benchmark in its portfolio positioning.
The fund is priced in US dollars. Among others, investment value is subject to foreign exchange risk, market risk and interest rate risk, and credit risk of the issuers.
|Risk of loss||
Moderate to high in periods shorter than five years. Subject to market volatility, lower in longer term.
|Security description||Asset class||Country of Listing||Portfolio weight %|
|Tencent Holdings Ltd||Equity||HK||5.1|
|Alibaba Group Holding Ltd||Equity||HK||4.4|
|JD.Com Inc - ADR||Equity||US||4.1|
|BioMarin Pharmaceutical Inc||Equity||US||3.8|
Monthly Commentary – December 2022
- Global equities (-3.9%) retraced on hawkish central bank rhetoric despite softer CPI prints, with emerging markets (-1.4%) outperforming developed markets (-4.2%) — global equities (-18.4%) fell sharply for 2022, with emerging markets (-20.1%) underperforming developed markets (-17.7%)
- Within developed markets, European bourses were flat, outperforming US counterparts (-5.9%) as European GDP surprised and on expectations that China’s reopening would benefit the region — US markets were rattled by persistent Fed hawkishness and poor near-term corporate earnings prospects
- Emerging market outperformance was led by China’s continued rebound (+5.2%) — reopening measures continued to prop up markets in addition to strong government support to stimulate the domestic economy
- Global sectors were negative in December, with utilities (+0.1%) the only exception — information technology (-7.8%) and consumer discretionary (-7.0%) led decliners as investors pulled out of riskier sectors
- The fund outperformed the index in December, with investments in Trip.com (+16.1%), Alibaba (+8.0%) and Tencent Holdings (+16.4%) being key contributors — for the year, the fund clawed back 400 basis points of 2021 underperformance
Management Fee (Percentage of the applicable Net Asset Value per share)
Class R: 0.85% + 15% of outperformance over the benchmark
The annual fee comprises a fixed standard fee plus a performance fee, subject to an overall minimum
The annual fee may be adjusted up daily (subject to fulfilling the performance conditions) by the performance fee, calculated as the difference between the portfolio performance and the benchmark return for the same period multiplied by the performance fee sharing rate
WHAT IF YOU HAD INVESTED WITH US IN THE PAST?
Experience the compounding phenomenon of a sustained, long-term investment with the Foord International Fund.